drugset / Trial / NCT04229264

Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients.

NCT04229264

RandomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy and safety of apixaban 2.5 mg twice daily plus aspirin compared to the standard treatment (clopidogrel plus aspirin) in patients with critical limb ischemia undergoing infrapopliteal arterial endovascular intervention.

Timeline

Start
2020-01-09
Primary completion
2022-02-02
Completion
2022-05-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule 2.5 mg Oral
Comparator Clopidogrel Small molecule 75 mg Oral
Background ASA Unknown 100 mg Oral

Indications